Zobrazeno 1 - 10
of 443
pro vyhledávání: '"medicine"'
Autor:
Myeong-Jin Kim, Jeong Min Lee, Anke-Peggy Holtorf, Abhasnee Sobhonslidsuk, Sith Phongkitkarun, Harald Rinde, Karsten Bergmann
Publikováno v:
Journal of Medical Economics. 19:759-768
The effectiveness of treatment decisions and economic outcomes of using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-MRI) were compared with extracellular contrast media-enhanced MRI (EC
Publikováno v:
Journal of Medical Economics. 19:718-727
Multiple sclerosis (MS) causes significant disability and diminished quality-of-life. Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) is a new oral treatment for relapsing-remitting MS (RRMS) approved in the US, Australia,
Autor:
S De Portu, William J. Valentine, Yves Reznik, Jayne Smith-Palmer, S Roze, E Duteil, H W de Valk, BF De Brouwer
Publikováno v:
Journal of Medical Economics. 19:742-749
Up to 30% of insulin-treated type 2 diabetes patients are unable to achieve HbA1c targets despite optimization of insulin multiple daily injections (MDI). For these patients the use of continuous subcutaneous insulin infusion (CSII) represents a usef
Publikováno v:
Journal of Medical Economics. 19:696-701
Introduction Mitral regurgitation is a heart condition resulting from blood flowing from the left ventricle towards the left atrium, increasing the risk of heart failure and mortality. While surgery can greatly reduce these risks, some patients are n
Autor:
Anders Winther, Jakob Nørgaard Andreasen, Steen Meier Ronborg, Sune Theilgaard, Claus R. Johnsen, Julie Hahn-Pedersen, Jens Olsen
Publikováno v:
Journal of Medical Economics. 19:735-741
Objectives Currently, patients with persistent moderate-to-severe house dust mite (HDM) allergic rhinitis despite use of symptom-relieving medication can be offered subcutaneously administered allergy immunotherapy (SQ SCIT; Alutard SQ) as standard c
Publikováno v:
Journal of Medical Economics. 19:710-717
Objective Hidradenitis suppurativa (HS) is often treated by surgery. The risk of recurrence after surgery is common and the consequences are substantial, but neither has been quantified using a claims database. This study aimed to estimate the burden
Publikováno v:
Journal of Medical Economics. 19:684-695
Objective Peginterferon beta-1a 125 mcg, administered subcutaneously (SC) every 2 weeks, a new disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), was approved by the US Food and Drug Administration in 2014. This study
Publikováno v:
Journal of Medical Economics. 19:663-671
Objective: Ranibizumab, an anti-vascular endothelial growth factor designed for ocular use, has been deemed cost-effective in multiple indications by several Health Technology Assessment bodies. This study assessed the cost-effectiveness of ranibizum
Publikováno v:
Journal of Medical Economics. 19:672-683
Objective To compare the cost-utility of the glucagon-like peptide-1 receptor agonist albiglutide with those of insulin lispro (both in combination with insulin glargine), insulin glargine, and the dipeptidyl peptidase-4 inhibitor sitagliptin, repres
Autor:
Jonathan Bouchard, Sheldon X. Kong, Brian Sakurada, Y. Liang, Edward S. Kimball, Todd Hobbs, Wayne Weng
Publikováno v:
Journal of Medical Economics. 19:655-662
Objective To explore trends in demographics, comorbidities, anti-diabetic drug usage, and healthcare utilization costs in patients with newly-diagnosed type 2 diabetes mellitus (T2DM) using a large US claims database. Methods For the years 2007 and 2